These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11956112)

  • 1. The "unsympathetic" nervous system of heart failure.
    Floras JS
    Circulation; 2002 Apr; 105(15):1753-5. PubMed ID: 11956112
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
    Cohn JN; Pfeffer MA; Rouleau J; Sharpe N; Swedberg K; Straub M; Wiltse C; Wright TJ;
    Eur J Heart Fail; 2003 Oct; 5(5):659-67. PubMed ID: 14607206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma catecholamines and chronic congestive heart failure.
    Lechin F; Lechin M; van der Dijs B
    Circulation; 2002 Dec; 106(25):e222; author reply e222. PubMed ID: 12485972
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
    Swedberg K; Bristow MR; Cohn JN; Dargie H; Straub M; Wiltse C; Wright TJ;
    Circulation; 2002 Apr; 105(15):1797-803. PubMed ID: 11956122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sympatholysis and cardiac sympathetic nerve function in the treatment of congestive heart failure.
    Liang CS
    J Am Coll Cardiol; 2003 Aug; 42(3):549-51. PubMed ID: 12906987
    [No Abstract]   [Full Text] [Related]  

  • 6. The economics of therapeutic advances: the paradigm of sympathetic suppression in chronic heart failure.
    Gavras I; Manolis AJ; Gavras H
    Arch Intern Med; 1999 Dec 13-27; 159(22):2634-6. PubMed ID: 10597753
    [No Abstract]   [Full Text] [Related]  

  • 7. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological properties of the central antihypertensive agent, moxonidine.
    Edwards LP; Brown-Bryan TA; McLean L; Ernsberger P
    Cardiovasc Ther; 2012 Aug; 30(4):199-208. PubMed ID: 21884003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease.
    Hausberg M; Tokmak F; Pavenstädt H; Krämer BK; Rump LC
    J Hypertens; 2010 Sep; 28(9):1920-7. PubMed ID: 20634720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [State of the sympathetic-adrenal system in congestive cardiac insufficiency].
    Korochkin IM; Oganov RG
    Kardiologiia; 1973 Mar; 13(3):140-51. PubMed ID: 4149940
    [No Abstract]   [Full Text] [Related]  

  • 11. [The modulatory influence of moxonidine on the different link of sympatho-adrenal system and hemodynamic reactions in normo and hypertensive rats during emotional stress].
    Bakuridze KA; Gongadze NV
    Georgian Med News; 2006 Apr; (133):120-4. PubMed ID: 16705249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure.
    Mulligan IP; Fraser AG; Lewis MJ; Henderson AH
    Br Heart J; 1989 Jan; 61(1):23-8. PubMed ID: 2537095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril).
    Kluger J; Cody RJ; Laragh JH
    Am J Cardiol; 1982 May; 49(7):1667-74. PubMed ID: 7044087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adrenergic activation in heart failure: blockade or rebalance?].
    Emdin M; Vergaro G; Giannoni A; Passino C
    G Ital Cardiol (Rome); 2010 Mar; 11(3):229-32. PubMed ID: 20550063
    [No Abstract]   [Full Text] [Related]  

  • 15. Abnormalities of peripheral sympathetic nervous system control in congestive heart failure.
    Cohn JN
    Circulation; 1990 Aug; 82(2 Suppl):I59-67. PubMed ID: 1973641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
    Neumann J; Ligtenberg G; Oey L; Koomans HA; Blankestijn PJ
    J Am Soc Nephrol; 2004 Nov; 15(11):2902-7. PubMed ID: 15504943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.
    Azevedo ER; Kubo T; Mak S; Al-Hesayen A; Schofield A; Allan R; Kelly S; Newton GE; Floras JS; Parker JD
    Circulation; 2001 Oct; 104(18):2194-9. PubMed ID: 11684630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure.
    Hegde SS; Friday KF
    Curr Pharm Des; 1998 Dec; 4(6):469-79. PubMed ID: 10197057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of captopril versus milrinone therapy in modulating the adrenergic nervous system response to exercise in congestive heart failure.
    Corbalán R; Jalil J; Chamorro G; Casanegra P; Valenzuela P
    Am J Cardiol; 1990 Mar; 65(9):644-9. PubMed ID: 2178384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of biomarkers in the management of heart failure: are we there yet?
    Bozkurt B; Mann DL
    Circulation; 2003 Mar; 107(9):1231-3. PubMed ID: 12628938
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.